Phase 3
Completed N=703
A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).
Carcinoma · Non-Small-Cell Lung
Source: ClinicalTrials.gov NCT00863746 ↗
Enrolled (actual)
703
Serious AEs
35.4%
Results posted
Jul 2013
Primary outcomePrimary: Overall Survival — 248; 253 Days — p=0.4687
Summary
The purpose of the study is to see if sorafenib plus best supportive care (i.e. in addition to the non-cancer treatments patients would normally receive) is an effective treatment for lung cancer compared to best supportive care alone. The safety and tolerability of the two treatment groups will also be compared. The goal of the study is to test the ability of sorafenib to improve survival compared to best supportive care alone.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Survival |
248; 253 | 0.4687 |
| SECONDARY Progression-free Survival |
84; 43 | <0.0001 sig |
| SECONDARY Disease Control |
0.4714; 0.2465 | <0.000001 sig |
| SECONDARY Objective Tumor Response |
0.0486; 0.0085 | 0.000876 sig |
| SECONDARY Time to Progression |
89; 43 | <0.0001 sig |
| SECONDARY Mean Change From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire for Palliative Care (EORTC QLQ-C15-PAL) - Global Health Status |
-6.158; -3.398; -5.222; -2.305; -2.763; -3.782 | 0.3121 |
| SECONDARY Mean Change From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire Lung Cancer Module (EORTC QLQ-LC13) - Coughing Subscale |
0.786; 2.866; -1.567; -0.174; -2.674; 0.000 | 0.2948 |
| SECONDARY Mean Change From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire Lung Cancer Module (EORTC QLQ-LC13) - Dyspnea |
3.678; 3.740; 0.958; 2.058; 3.226; 2.963 | 0.8344 |
| SECONDARY Mean Change From Baseline in EuroQol-5D (EQ-5D) - Index Score |
-0.0627; -0.0386; -0.0439; -0.0728; -0.1845; -0.1442 | 0.1438 |
| SECONDARY Mean Change From Baseline in EuroQol-5D (EQ-5D) - VAS Score |
-3.73; -3.48; -5.39; -2.48; -12.72; -10.75 | 0.9228 |
Eligibility Criteria
Inclusion Criteria
- Ability to understand and willingness to sign a written Informed Consent
- Advanced relapsed or refractory predominantly non squamous NSCLC. The diagnosis must have been confirmed cyto-/ histologically
- Patients must have measurable or non-measurable disease
- At least two but not more than three prior standard treatment regimens for NSCLC
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Male or female subjects >/= 18 years of age (>/=20 for Japan) at the time of Informed Consent
- Life expectancy of at least 12 weeks
- Ability to swallow oral medication
- Both men and women using adequate barrier birth control measures during the course of the trial and 4 weeks after the completion of trial
- Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of the study drug:
- Haemoglobin > 9.0 g/dl
- Absolute neutrophil count (ANC) >1,500/mm3
- Platelet count >/= 100,000/µl
- Total bilirubin /= 50 mL/min
Exclusion Criteria
- NSCLC patients with predominantly squamous cell carcinoma histology
Excluded medical conditions:
- History of cardiac disease: Congestive heart failure, Active coronary artery disease (CAD), Cardiac arrhythmias (>Grade 2 NCI-CTCAE [National Cancer Institute-Common Terminology Criteria for Adverse Events] vers. 3.0)
- Uncontrolled hypertension despite two anti-hypertensive medications
- History of Human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
- History of organ allograft
- Active clinically serious infections (> grade 2 NCI-CTCAE vers. 3.0)
- Patients with seizure disorder requiring medication
- Patients with evidence or history of bleeding diathesis or coagulopathy
- Patients undergoing renal dialysis
- Pulmonary hemorrhage/ bleeding event >/= CTCAE grade 2 within four weeks prior to the first dose of the study drug
- Any other hemorrhage/ bleeding event >/= CTCAE grade 3 within four weeks prior to the first dose of the study drug
- Thrombotic or embolic venous or arterial events such as cerebrovascular accident
- Pregnant or breast-feeding women.
- Any condition which could affect the absorption or pharmacokinetics of the study drug
- Prior treatment with other Vascular Endothelial Growth Factor (VEGF) (R) inhibitors, including compounds that impact vascularity (i.e. sunitinib, thalidomide, vandetanib, vascular disrupting agents [VDA], VEGF-trap and other experimental agents of this class). Only bevacizumab (Avastin) is permitted.
Data sourced from ClinicalTrials.gov (NCT00863746). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.